Latest Articles

Publication Date
All News Scientific
Lipid-lowering agents linked to improved survival in women with endometrial Ca - Contemporary OB/GYN

Lipid-lowering agents linked to improved survival in women with endometrial Ca Contemporary OB/GYN

Published: Sept. 8, 2026, 8 p.m.
Read Full Article
Insured Black patients face lower endometrial cancer survival than White - Bioengineer.org

Insured Black patients face lower endometrial cancer survival than White Bioengineer.org

Published: Aug. 15, 2026, 12:43 a.m.
Read Full Article
Insured Black patients face lower endometrial cancer survival than White - bioengineer.org

Insured Black patients face lower endometrial cancer survival than White bioengineer.org

Published: Aug. 15, 2026, 12:43 a.m.
Read Full Article
Insured Black patients face lower endometrial cancer survival than White patients - Bioengineer.org

Insured Black patients face lower endometrial cancer survival than White patients Bioengineer.org

Published: Aug. 15, 2026, 12:42 a.m.
Read Full Article
Giuseppe Caruso: KEYTRUDA Improves Progression-Free Survival in Frontline dMMR Endometrial Cancer - Oncodaily

Giuseppe Caruso: KEYTRUDA Improves Progression-Free Survival in Frontline dMMR Endometrial Cancer Oncodaily

Published: July 16, 2026, 4:40 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace

Published: July 15, 2026, 3:11 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire

Published: July 15, 2026, 10:45 a.m.
Read Full Article
Dostarlimab Boosts Long-Term Survival in Endometrial Cancer - Medscape

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer Medscape

Published: June 22, 2026, 1 p.m.
Read Full Article
Trastuzumab Pamirtecan Provides Meaningful Survival Benefit in Pretreated HER2-Expressing Endometrial Cancer - OncLive

Trastuzumab Pamirtecan Provides Meaningful Survival Benefit in Pretreated HER2-Expressing Endometrial Cancer OncLive

Published: June 17, 2026, 9:31 p.m.
Read Full Article
PD-1 Inhibitors Improve Survival for dMMR Endometrial Cancer - Medscape Reference

PD-1 Inhibitors Improve Survival for dMMR Endometrial Cancer Medscape Reference

Published: June 17, 2026, 2:51 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!